Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis - Poll - MDSpire

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis

  • By

  • Philipp Berning

  • Markus Maulhardt

  • Hristo Boyadzhiev

  • Anca-Maria Albici

  • Snjezana Janjetovic

  • Anna Ossami Saidy

  • Christian Schultze-Florey

  • Simon Call

  • Friedrich Stölzel

  • Annamaria Brioli

  • Michael Daskalakis

  • Juliane Knust

  • Justin Hasenkamp

  • Rebecca Wurm-Kuczera

  • Alexander Pohlmann

  • Matthias Stelljes

  • Cyrus Khandanpour

  • Ulrike Bacher

  • Amelie Boquoi

  • Florian H. Heidel

  • Hans Christian Reinhardt

  • Gerald Wulf

  • Natalie Schub

  • Bastian von Tresckow

  • Georg Lenz

  • Thomas Pabst

  • Evgenii Shumilov

  • June 2, 2026

  • 0 min

Share

Original Source(s)

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis

  • by Philipp Berning, Markus Maulhardt, Hristo Boyadzhiev, Anca-Maria Albici, Snjezana Janjetovic, Anna Ossami Saidy, Christian Schultze-Florey, Simon Call, Friedrich Stölzel, Annamaria Brioli, Michael Daskalakis, Juliane Knust, Justin Hasenkamp, Rebecca Wurm-Kuczera, Alexander Pohlmann, Matthias Stelljes, Cyrus Khandanpour, Ulrike Bacher, Amelie Boquoi, Florian H. Heidel, Hans Christian Reinhardt, Gerald Wulf, Natalie Schub, Bastian von Tresckow, Georg Lenz, Thomas Pabst, Evgenii Shumilov

  • June 2, 2026

Related Content

Case series analysis of immunophenotypic evolution during recurrence of low-grade endometrial stromal sarcoma: implications for molecular stability and clinical management

Case Report: Intramedullary solitary fibrous tumor at the C7-T1 level diagnosed by STAT6 and treated with maximal safe resection

Signals of inequity in the care pathway: rural lab diagnosis, systemic therapy delays, and RAS mutation differences in metastatic colorectal cancer